"Tolbutamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Descriptor ID |
D014044
|
MeSH Number(s) |
D02.886.590.795.896 D02.948.828.896
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tolbutamide".
Below are MeSH descriptors whose meaning is more specific than "Tolbutamide".
This graph shows the total number of publications written about "Tolbutamide" by people in this website by year, and whether "Tolbutamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1997 | 0 | 2 | 2 |
1998 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2010 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tolbutamide" by people in Profiles.
-
Calcium-activated and voltage-gated potassium channels of the pancreatic islet impart distinct and complementary roles during secretagogue induced electrical responses. J Physiol. 2010 Sep 15; 588(Pt 18):3525-37.
-
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29; 323(2):246-55.
-
Improved outcomes in islet isolation and transplantation by the use of a novel hemoglobin-based O2 carrier. Am J Transplant. 2006 Dec; 6(12):2861-70.
-
Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001 Feb; 50(2):322-8.
-
Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice. J Biol Chem. 1998 Sep 18; 273(38):24457-64.
-
Evidence that insulin can directly inhibit hepatic glucose production. Diabetologia. 1997 Nov; 40(11):1300-6.
-
Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes. 1997 Apr; 46(4):726-30.
-
PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science. 1996 Feb 09; 271(5250):813-5.
-
A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide versus insulin infusion. J Clin Endocrinol Metab. 1994 Jul; 79(1):66-70.
-
Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes. 1994 Jan; 43(1):40-6.